Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAF1) with blood pressure

Clinical Genetics
Marlys L KoschinskyR A Hegele

Abstract

Thrombin-activable fibrinolysis inhibitor (TAFI) is a hepatically secreted zymogen, whose substrates include bradykinin. The CPB2 gene encoding TAFI is a candidate gene for blood pressure. A recently identified single nucleotide polymorphism (SNP) in the CPB2 coding region, designated as 1057C > T, results in an amino acid change at TAFI residue 325 (Ile > Thr325). We found that the genotype based on this SNP was significantly associated with blood pressure in aboriginal Canadians. Specifically, analysis of variance showed that homozygotes for CPB2 1057T had significantly lower diastolic blood pressure than subjects with other CPB2 genotypes. CPB2 genotype accounted for approximately 3% of the total variation in diastolic blood pressure. consistent with the expected magnitude of a modest genetic effect in a complex trait such as blood pressure. Although the mechanism underlying the association is unclear, the findings are of interest because TAFI may provide a link between coagulation and blood pressure regulation.

References

Jan 1, 1991·Epidemiologic Reviews·M L BotsA Hofman
Mar 1, 1991·The American Journal of Medicine·A Amery, A De Schaepdryver
May 1, 1989·Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift Für Klinische Chemie Und Klinische Biochemie·D HendriksM P Lommaert
Jul 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·R A HegeleP W Connelly
Jan 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·R A HegeleP W Connelly
Jun 16, 1995·The Journal of Biological Chemistry·L BajzarM E Nesheim
Jan 1, 1994·International Archives of Allergy and Immunology·T ShinoharaH Okada
May 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·R A HegeleP W Connelly
Nov 1, 1996·Clinical and Experimental Hypertension : CHE·Q SongL Chao
Jan 14, 1999·Journal of Hypertension·F C Luft
Nov 24, 1999·American Journal of Hypertension·C Emanueli, P Madeddu
Dec 22, 1999·Immunopharmacology·S NaickerK Bhoola
Sep 7, 2000·Cardiovascular Research·C LabinjohD J Webb
Feb 24, 2001·Hypertension·Carlos D. FigueroaWerner Müller-Esterl

❮ Previous
Next ❯

Citations

Feb 10, 2006·Genome Research·P V Krishna PantKelly A Frazer
Jan 4, 2005·American Journal of Nephrology·Jolanta MałyszkoMichał Myśliwiec
Feb 5, 2005·Pathophysiology of Haemostasis and Thrombosis·Bonno N Bouma, Laurent O Mosnier
Sep 30, 2006·Annals of Medicine·Bonno N Bouma, Laurent O Mosnier
Oct 4, 2003·The Journal of Biological Chemistry·Timothy MylesLawrence L K Leung
May 1, 2004·Critical Care Medicine·Laszlo BajzarJohn B Walker
May 1, 2013·Hypertension·Annette von DrygalskiMatthew Allison
Oct 6, 2005·Shock·John ArcaroliEdward Abraham
Apr 18, 2015·Molecular Systems Biology·Tianxiao HuanDaniel Levy
May 1, 2021·International Journal of Molecular Sciences·Machteld Sillen, Paul J Declerck

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.